Company / Debt per Share
Myriad Genetics, Inc. Debt per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$1.48
FY2025
5-year range
$0.00 / $1.48
FY2021-FY2025
Trend
+198.3%
vs FY2024
Sector context
#49 of 82
Health Care
What the data says
At $1.48, Myriad Genetics, Inc.'s debt per share ranks #34 of 82 in the Health Care sector. Debt per Share has fluctuated over the past 9 years, ranging from $0.00 in FY2022 to $3.38 in FY2019.
Based on SEC 10-K filings.
1.48 in FY2025 with a 5-year CAGR of -14.8%.
Increased from $0.51 to $1.48 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -14.8%
- 10-Year CAGR
- -
Sector benchmark
#34 of 82 in Health CareTop 40% of 82This company $1.48 Sector average $126.59
▼
-98.8% below sector average
Key checks
Key Insights
- In FY2025, debt per share increased 198.3% year-over-year.
- Ranks #49 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2019.
- Lowest debt per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.48 | +198.3% |
| FY2024 | $0.49 | -3.1% |
| FY2023 | $0.51 | - |
| FY2022 | $0.00 | - |
| FY2021 | $0.00 | -100.0% |
| FY2020 | $3.29 | -2.7% |
| FY2019 | $3.38 | +2403.5% |
| FY2018 | $0.13 | -90.0% |
| FY2017 | $1.35 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026